Search - tctmd.com

Displaying 61 - 80 of 110

Sort: Relevancy | Date

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

Todd Neale

November 06, 2022

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

News Daily News

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

L.A. McKeown

October 05, 2022

GDMT With ARNI Lessens MR, Perhaps Obviating Need for Interventions

News Conference News HFSA 2022

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

Michael O'Riordan

October 04, 2022

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Shelley Wood

July 25, 2022

News Daily News

Comorbidities May Drive PAD Procedural Outcomes in Black Patients

L.A. McKeown

June 23, 2022

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

L.A. McKeown

May 05, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

News Daily News

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Caitlin E. Cox

January 10, 2022

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

L.A. McKeown

December 07, 2021

News Conference News AHA 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Michael O'Riordan

November 19, 2021

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Shelley Wood

November 08, 2021

News Conference News HFSA 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

Todd Neale

September 13, 2021

News Daily News

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Todd Neale

July 06, 2021

Advertisement

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

CV Care Around Noncardiac Surgery: New ESC Guidelines

What’s Going to Be Hot at ESC 2022?

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Comorbidities May Drive PAD Procedural Outcomes in Black Patients

Dapagliflozin Boosts Health Status Across LVEF Range

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

FDA Approves Empagliflozin for Treatment of HFpEF

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Canagliflozin Improves Quality of Life in HF Patients

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content